IDYA News and Press, IDEAYA Biosciences Inc. From 04/24/23

2023-04-24 16:32:22 ET IDEAYA Biosciences ( NASDAQ: IDYA ) on Monday announced a proposed public stock offering of up to $150M. IDYA also said it intends to grant the underwriters a 30-day option to purchase up to $22.5M of shares of its common stock. The announcement ...

2023-04-24 16:27:10 ET IDEAYA Biosciences ( NASDAQ: IDYA ) has filed for an underwritten public offering for $150M worth of its common stock. J.P. Morgan, Jefferies and Citigroup are joint bookrunners. Underwriters have been granted a 30-day option to purchase up to ...

2023-04-24 13:50:08 ET IDEAYA Biosciences ( NASDAQ: IDYA ) climbed ~25% Monday marking the biggest intraday gain since September after announcing plans to begin a Phase 2/3 registrational trial in Q2 2023 for its lead program for experimental cancer therapies darovasertib and cr...

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is one of today's top gainers. The company's shares are currently up 25.79% on the day to $18.78. IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeuti...

2023-04-24 10:08:54 ET Gainers: IN8bio ( INAB ) +121% . IDEAYA Biosciences ( IDYA ) +27% . ZyVersa Therapeutics ( ZVSA ) +26% .  Koninklijke Philips ( PHG ) +15% . Kiora Pharmaceuticals ( KPRX ) +9% . Losers: Scilex H...

2023-04-24 09:13:31 ET Getty Images Holdings ( GETY ) +59% proposes to acquire Getty Images for $10 per share. IN8bio ( INAB ) +38% Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Tre...

2023-04-23 12:00:00 ET Biotech deal-making is on a roll, with more than $12B worth of transactions announced over the past week alone, and, according to industry observers, the trend is expected to continue in 2023, supported by macro and certain industry-specific factors. Days after Me...

IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma PR Newswire Confirmed overall response rate (ORR) of 45%...

2023-04-19 09:01:34 ET With several large M&A deals involving biotechs being acquired so far in 2023, RBC Capital Markets says such activity could be on the rise ahead. Given recent M&A activity, we "remind investors that there remains M&A appetite among large pharmas,...

IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First-in-Class PARG Inhibitor Targeting HRD Solid Tumors PR Newswire - Evaluating IDE161 in patients having solid tumors with HRD, with expansion focus in ER+ / Her2- breast cancer with HRD, r...